# GLP-1s and Inflammatory Bowel Disease

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/glp1-and-inflammatory-bowel-disease

> The pivotal trials excluded people with IBD, so the evidence is retrospective: 13 of 14 studies. It has not linked GLP-1s to more flares, and that null result deserves careful reading.

## Key points

- The pivotal trials excluded people with IBD, so the question was never asked.
- 14 studies, 13 of them retrospective cohorts. No randomized trial exists.
- No association with increased IBD exacerbations across multiple datasets.
- Clinicians prescribe less during flares, which biases a null result toward reassurance.

If you have Crohn’s disease or ulcerative colitis, the obvious worry about a drug that deliberately slows the gut is whether it will stir up your gut. The pivotal trials cannot tell you, because **people with IBD were excluded from them**.[1] What exists instead is a body of retrospective evidence assembled afterwards. The useful questions are what it says and how much weight it can carry.

## What the review found

A 2026 systematic review searched the literature to September 2025 and found 14 studies of GLP-1 drugs in adults with IBD. Ten reported significant reductions in body weight, BMI or percentage weight loss. Four showed improvements in metabolic markers, including lower HbA1c and more favorable lipids.[1]

On the main worry, across multiple datasets GLP-1 use was **not associated with increased IBD exacerbations**.[1] That is the headline, and it is reassuring as far as it goes.

> **Thirteen of those fourteen studies were retrospective cohorts.** There is no randomized trial here. That matters more than usual for a reassuring null result, because of who gets prescribed: a gastroenterologist is less likely to start a weight-loss drug in someone whose disease is flaring. Healthier patients receiving the drug would produce exactly this finding even if the drug did nothing. The result is consistent with safety; it does not establish it.

## Why the question is reasonable in the first place

These drugs delay gastric emptying and slow transit, and their commonest adverse effects (nausea, diarrhea, abdominal pain, constipation) are the same symptoms that IBD produces and that patients and clinicians use to judge whether disease is active.

That overlap is a practical problem separate from any question of harm. New abdominal pain and altered stool on a GLP-1 could be the drug settling in or a flare beginning, and telling those apart is difficult. Our [side-effect timeline](https://glpwatchdog.org/research/how-long-do-glp1-side-effects-last) covers what the ordinary course looks like, which is the baseline you would be comparing against.

> Nausea, diarrhea, abdominal pain and constipation are both the drug’s commonest adverse effects and the symptoms used to judge whether IBD is active.

## The case for treating it anyway

The review opens by noting that obesity and metabolic disease are increasingly common in people with IBD, and they influence disease activity and how well treatment works.[1] This is not a population where excess weight is cosmetic.

So the choice is between two managed risks, in a person who often has fewer good options than average. That is a decision for a gastroenterologist who knows your disease history, not one to make from a website, and it is the kind of case where the specialist’s judgment is doing most of the work.

## What would change the picture

- **A randomized trial that includes people with IBD.** The single thing that would convert this from consistent-with-safety to established.
- **Prospective data with disease activity scored properly**, rather than exacerbations inferred from records where a flare and a side effect can look identical.
- **Separate answers for Crohn’s and colitis.** They behave differently, and the current evidence largely does not distinguish them.
- **Data on people with surgical history or strictures**, where slowed transit is a more specific concern than it is in inflammatory disease generally.

## Frequently asked questions

### Can you take a GLP-1 with Crohn's disease or ulcerative colitis?

People with IBD do take them, and the available evidence has not linked it to more flares. But people with IBD were excluded from the pivotal trials, so that evidence is retrospective. In a 2026 systematic review, 13 of 14 studies were retrospective cohorts. It is a decision for your gastroenterologist.

### Do GLP-1 drugs make IBD flare?

Across multiple datasets in a 2026 systematic review, GLP-1 use was not associated with increased IBD exacerbations. That is reassuring, with the caveat that clinicians are less likely to prescribe these drugs to someone whose disease is active, which would produce the same finding even if the drug had an effect.

### How do I tell a flare from a side effect?

With difficulty. Nausea, abdominal pain, diarrhea and constipation are both the drug's common adverse effects and the symptoms used to judge disease activity. That overlap is a reason to involve your IBD team when starting, rather than to interpret new symptoms yourself.

### Do they work as well in people with IBD?

Roughly, as far as anyone can tell. The few studies that compared people with and without IBD found small differences in both directions. Ten of the fourteen studies reported significant reductions in weight or BMI, and four showed metabolic improvements including lower HbA1c. The evidence base is small and retrospective, so the effect size is less certain than in the general population.

## References

1. Maracle B, Quan S, Hamilton P, et al. Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP-1 Receptor Agonists in Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics. 2026. PMID: 41319219. https://pubmed.ncbi.nlm.nih.gov/41319219/

---

Cite as: GLP Watchdog, Nora Bissett, "GLP-1s and Inflammatory Bowel Disease", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/glp1-and-inflammatory-bowel-disease

Canonical HTML page: https://glpwatchdog.org/research/glp1-and-inflammatory-bowel-disease

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
